title: Recurrent ovarian cancer.
abstract: Recurrence still occurs in a majority of patients with advanced ovarian cancer. However, progress in the management has allowed a significant prolongation of survival for relapsing disease. These last years, the field of interest has moved from chemotherapy to targeted therapy which is dominated by anti-angiogenic and anti-PARP agents. It is assumed that platinum-free interval will not remain the main prognostic and predictive criterion in the future, and will be replaced by a multi-factorial approach. This trend for personalization of therapy has highlighted important neglected fields for clinical research such as multi-line (≥3) relapse, frail patients including elderly and symptomatic and supportive measures.
authors.affiliation: Université Paris Descartes, APHP, Hôpital Hôtel-Dieu, Paris epujade@arcagy.org.
authors.forename: E
authors.initials: E
authors.lastname: Pujade-Lauraine
authors.affiliation: Université Paris Descartes, APHP, Hôpital Européen Georges Pompidou, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Combe
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents